Philogen Provides Corporate Update

Philogen Provides Corporate Update 211 out of 214 patients recruited in European Phase III trial investigating the neoadjuvant Nidlegy treatment of Stage IIIB/C melanoma, in line with expectations.Fibromun further

Related Keywords

Germany ,Italy ,Poland ,Switzerland ,France ,Spain ,Italian ,Swiss ,Mary Jane Elliott ,Davide Salvi ,Le Rhun ,Dario Neri ,Philogen Group Description ,Consilium Strategic Communications ,Philogen Provides Corporate Update ,Senn Chemicals ,Chief Executive Officer ,Tumor Necrosis Factor ,Cancer Treat Rev ,Fibroblast Activation Protein ,Antibody Phage Display Libraries ,Encodedchemical Library ,Strategic Communications ,Jane Elliott ,Philogen ,Rovides ,Corporate ,Update ,